Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) rose 4% during trading on Thursday after Stifel Nicolaus raised their price target on the stock from $50.00 to $55.00. Stifel Nicolaus currently has a buy rating on the stock. Aerie Pharmaceuticals traded as high as $40.95 and last traded at $40.83, with a volume of 713,318 shares trading hands. The stock had previously closed at $39.26.
A number of other analysts have also commented on the company. HC Wainwright initiated coverage on Aerie Pharmaceuticals in a research note on Tuesday, September 20th. They set a “buy” rating and a $66.00 price target on the stock. Raymond James Financial Inc. assumed coverage on Aerie Pharmaceuticals in a research report on Tuesday, September 13th. They set an “outperform” rating and a $48.00 price objective for the company. Brean Capital restated a “buy” rating and set a $48.00 price objective on shares of Aerie Pharmaceuticals in a research report on Wednesday, September 7th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and set a $45.00 price objective on shares of Aerie Pharmaceuticals in a research report on Tuesday, August 23rd. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $51.40.
In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of the stock in a transaction on Friday, July 22nd. The stock was acquired at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 8.77% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the company. Spark Investment Management LLC acquired a new stake in shares of Aerie Pharmaceuticals during the first quarter worth $1,968,000. Geode Capital Management LLC increased its stake in shares of Aerie Pharmaceuticals by 0.6% in the first quarter. Geode Capital Management LLC now owns 161,319 shares of the company’s stock worth $1,961,000 after buying an additional 925 shares during the last quarter. Kennedy Capital Management Inc. increased its stake in shares of Aerie Pharmaceuticals by 14.3% in the first quarter. Kennedy Capital Management Inc. now owns 54,296 shares of the company’s stock worth $660,000 after buying an additional 6,787 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Aerie Pharmaceuticals by 24.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,025,000 shares of the company’s stock worth $24,624,000 after buying an additional 400,000 shares during the last quarter. Finally, A.R.T. Advisors LLC increased its stake in shares of Aerie Pharmaceuticals by 126.7% in the first quarter. A.R.T. Advisors LLC now owns 172,032 shares of the company’s stock worth $2,091,000 after buying an additional 96,145 shares during the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.
The firm’s market capitalization is $1.13 billion. The firm has a 50 day moving average price of $27.34 and a 200 day moving average price of $19.13.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.02. Analysts anticipate that Aerie Pharmaceuticals Inc. will post ($2.80) EPS for the current year.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.